What are the key insights from James Hicks's interview with BioRestorative CEO Lalstodt?

Hi there! I recently sat down 1:1 with Lance Alstodt, President, CEO and Chairman of BioRestorative Therapies, a company focused on regenerative biology and stem cell therapies for highly prevalent conditions.

Based on that conversation, here are the big takeaways:

1. BioRestorative is moving from early development into more advanced clinical trials, funded in part by its uplist from OTC to Nasdaq
2. The core mission is to address unmet patient needs with stem cell–based treatments, not just incremental therapies
3. There’s active work on educating the public and countering skepticism around stem cells with data and transparent studies
4. The team is focused on what they’re doing for patients today and how to follow their clinical studies and upcoming milestones

Would you like a short, patient-focused summary or a more investor-focused one?